Prophylactic immunosuppression with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two-year follow-up study

Raymond Reding, Axel Feyaerts, Hubert Vraux, Dominique Latinne, Bernardo De La Parra, Anne Cornet, Françoise Cormont, Jacques Jamart, Etienne Sokal, Jean De Ville De Goyet, Jan Lerut, Hervé Bazin, Jean Bernard Otte

Research output: Contribution to journalArticle

Abstract

A prospective trial was conducted in 129 recipients of primary liver transplantation, to compare induction immunosuppression using triple drug therapy (cyclosporine, steroids, and azathioprine; group 1, n=42), versus triple drug therapy with a 10-day course of OKT3 (group 2, n=44) or of the anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 (group 3, n=43). Two-year actual patient survival rates were 64%, 79%, and 93% in groups 1, 2, and 3, respectively (1 vs. 2, NS; I vs. III, P=0.003; 2 vs. 3, NS). Up to 2 years after transplantation, 18%, 44%, and 53% of the grafts in groups 1, 2, and 3, respectively, had not experienced steroid-resistant acute rejection (1 vs. 2, P=0.002; 1 vs. 3, P=0.007; 2 vs. 3, NS). The overall incidence of chronic rejection was 4%. OKT3 therapy, but not LO-Tact-1, significantly increased the incidence of cytomegalovirus infections (P=0.019). In conclusion, immunoprophylaxis with LO-Tact-1 seemed to provide a liver graft acceptance rate at least as satisfactory as that with OKT3, without an increase in the incidence of infections.

Original languageEnglish
Pages (from-to)1406-1409
Number of pages4
JournalTransplantation
Volume61
Issue number9
Publication statusPublished - May 15 1996

ASJC Scopus subject areas

  • Immunology
  • Transplantation

Fingerprint Dive into the research topics of 'Prophylactic immunosuppression with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two-year follow-up study'. Together they form a unique fingerprint.

  • Cite this

    Reding, R., Feyaerts, A., Vraux, H., Latinne, D., De La Parra, B., Cornet, A., Cormont, F., Jamart, J., Sokal, E., De Ville De Goyet, J., Lerut, J., Bazin, H., & Otte, J. B. (1996). Prophylactic immunosuppression with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two-year follow-up study. Transplantation, 61(9), 1406-1409.